PLX

We rate Protalix BioTherapeutics, Inc. (PLX) as a Hold with a composite score of 57.6/100 at a current price of $3.01. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling for existing holders. Our factors are split, and the overall profile suggests patience is warranted.

The rating is primarily driven by strength in quality (65th percentile) and momentum (58th percentile), which together account for the majority of the composite score. Offsetting weakness in investment (27th percentile) and stability (48th percentile) tempers our overall conviction. We assign a Narrow Moat rating (48/100), High uncertainty, and Poor capital allocation.

Key items to watch: sustainability of the current growth rate; the path to profitability. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.

Protalix BioTherapeutics, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 57.6/100 places it at rank #945 in our full 7,333-stock universe. At $177M in market capitalization, Protalix BioTherapeutics, Inc. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.

Revenue is growing at 32%, though momentum at the 58th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.

The margin cascade tells an important story: gross margins of 47% (+4.6pp vs sector) narrow to operating margins of 0% (-1.1pp vs sector) and net margins of -0.9%, yielding a gross-to-net conversion rate of -2%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.

At a current price of $3.01, Protalix BioTherapeutics, Inc. is trading near fair value based on current fundamentals. Our value factor score of 57/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. Valuation metrics are mixed, with no strong signal of mispricing in either direction.

The stock currently trades at a P/E of 115.2x (a 418% premium to the sector median of 22.3x), EV/EBITDA of 82.1x (at a premium), P/B of 4.7x, P/S of 4.0x. The above-sector P/E multiple suggests the market is pricing in superior growth or quality, which our analysis partially supports given strong quality metrics.

We assign a High uncertainty rating to Protalix BioTherapeutics, Inc.. Key risk factors include current negative profitability (net margin -0.9%), elevated valuation multiple (P/E 115.2x) that leaves limited margin for error, the combination of leverage (55% D/E) and thin margins (-0.9% net) amplifies downside risk. The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.

Specific risk factors that inform our assessment include: current negative profitability (net margin -0.9%); elevated valuation multiple (P/E 115.2x) that leaves limited margin for error; the combination of leverage (55% D/E) and thin margins (-0.9% net) amplifies downside risk. Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 48th percentile and quality factor at the 65th percentile provide a quantitative summary of the overall risk landscape.

Key risk mitigants include: healthy gross margins of 47% provide a buffer against cost pressures. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.

We rate Protalix BioTherapeutics, Inc.'s capital allocation as Poor. Key concerns include low returns on equity (4.0%), negative profitability. Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — Protalix BioTherapeutics, Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.

Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.

In summary, Protalix BioTherapeutics, Inc. receives a Hold rating with a composite score of 57.6/100 (rank #945 of 7,333). Our quantitative framework assigns a Narrow Moat (48/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 51/100.

Our analysis supports a neutral stance on Protalix BioTherapeutics, Inc.. While the quantitative profile is not weak enough to warrant selling, it lacks the multi-factor strength required for a buy recommendation. Existing holders should maintain positions and monitor for catalysts — either fundamental improvement or valuation compression — that would shift the risk-reward balance.